Save Product
Product Details
Source
Biotinylated Monoclonal Anti-MMAE & MMAF Antibody, Mouse IgG1 is a recombinant mouse monoclonal antibody expressed in HEK293 cells and subsequently biotinylated.
Antibody Type
Recombinant Monoclonal
Clone
AS104
Isotype
Mouse IgG1, Kappa
Host Species
Mouse
Immunogen
MMAE
Conjugate
Biotinylated
Specificity
Specifically recognizes the target-MMAE&MMAF.
Application
ApplicationRecommended Use / PerformanceELISA1:200-1:2000Purification
Protein A purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Disitamab Vedotin (RC48) at 1 μg/mL (100 μL/well) can bind Biotinylated Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-BLS104) with a linear range of 2-31 ng/mL (QC tested).
Protocol
Immobilized Biotinylated Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-BLS104) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Disitamab Vedotin (RC48) with a linear range of 0.0078-0.125 ng/mL (Routinely tested).
Protocol
Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Disitamab Vedotin (RC48) in the 100% Human Serum and then add Biotinylated Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-BLS104) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Disitamab Vedotin (RC48) in the 0.5% BSA and then add Biotinylated Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-BLS104) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).
Protocol
Immobilized Human IgG1 Kappa Isotype Control (mAb)-MMAF at 1 μg/mL (100 μL/well) can bind Biotinylated Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-BLS104) with a linear range of 0.5-31 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
